[go: up one dir, main page]

MA28093A1 - Forme polymorphe de 3-phenylsulfonyl-8-piperazine-1-yl-quinoleine - Google Patents

Forme polymorphe de 3-phenylsulfonyl-8-piperazine-1-yl-quinoleine

Info

Publication number
MA28093A1
MA28093A1 MA28933A MA28933A MA28093A1 MA 28093 A1 MA28093 A1 MA 28093A1 MA 28933 A MA28933 A MA 28933A MA 28933 A MA28933 A MA 28933A MA 28093 A1 MA28093 A1 MA 28093A1
Authority
MA
Morocco
Prior art keywords
phenylsulfonyl
quinoline
piperazine
polymorph form
disorders
Prior art date
Application number
MA28933A
Other languages
English (en)
Inventor
Asa Elisabeth Gladwin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA28093A1 publication Critical patent/MA28093A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Forme polymorphe de 3-phénylsulfonyl-8 -pipérazine-1-yl- quinoléine Cette invention concerne un composé nouveau de 3- phénylsulfonyl-8-pipérazine-1-yl-quinoléine, des procédés pour sa préparation, des compositions le contenant et son utilisation dans le traitement de troubles du XX et d'autres troubles.
MA28933A 2003-09-26 2006-04-13 Forme polymorphe de 3-phenylsulfonyl-8-piperazine-1-yl-quinoleine MA28093A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0322629.7A GB0322629D0 (en) 2003-09-26 2003-09-26 Novel compound

Publications (1)

Publication Number Publication Date
MA28093A1 true MA28093A1 (fr) 2006-08-01

Family

ID=29286934

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28933A MA28093A1 (fr) 2003-09-26 2006-04-13 Forme polymorphe de 3-phenylsulfonyl-8-piperazine-1-yl-quinoleine

Country Status (23)

Country Link
US (1) US20070032504A1 (fr)
EP (1) EP1667975B1 (fr)
JP (1) JP2007506702A (fr)
CN (1) CN1856471A (fr)
AU (1) AU2004283805A1 (fr)
BR (1) BRPI0414678A (fr)
CA (1) CA2540022A1 (fr)
CO (1) CO5680402A2 (fr)
DE (1) DE602004010410T2 (fr)
DK (1) DK1667975T3 (fr)
ES (1) ES2297465T3 (fr)
GB (1) GB0322629D0 (fr)
HR (1) HRP20080055T3 (fr)
IL (1) IL174213A0 (fr)
IS (1) IS8399A (fr)
MA (1) MA28093A1 (fr)
MX (1) MXPA06003375A (fr)
NO (1) NO20061791L (fr)
PL (1) PL1667975T3 (fr)
PT (1) PT1667975E (fr)
RU (1) RU2355681C2 (fr)
WO (1) WO2005040124A1 (fr)
ZA (1) ZA200601453B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0308696B8 (pt) * 2002-03-27 2021-05-25 Axovant Sciences Gmbh composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos
BRPI0412263B1 (pt) 2003-07-22 2019-10-15 Arena Pharmaceuticals, Inc. Derivados de diaril e aril heteroaril uréia, uso e composição farmacêutica contendo os mesmos, bem como processo para preparação da dita composição
WO2005028429A2 (fr) 2003-09-18 2005-03-31 Axys Pharmaceuticals, Inc. Composes contenant un haloalkyle utilise comme inhibiteurs de cysteine protease
AU2006254255A1 (en) 2005-06-02 2006-12-07 F. Hoffmann-La Roche Ag 3-methanesulfonylquinolines as GABA-B enhancers
GB0519758D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel process
EP2120950B1 (fr) * 2007-03-21 2012-07-04 Glaxo Group Limited Utilisation de derives quinoleines pour le traitement de la douleur
WO2009074607A1 (fr) 2007-12-12 2009-06-18 Glaxo Group Limited Associations contenant de la 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (fr) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Procédés de préparation de dérivés de pyrazole utiles comme modulateurs du récepteur de la sérotonine 5-ht<sb>2a</sb>
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
EP4119141A1 (fr) 2015-06-12 2023-01-18 Axovant Sciences GmbH Nelotanserin pour la prophylaxie et le traitement d'un trouble du comportement en sommeil paradoxal
EP3322415A4 (fr) 2015-07-15 2019-03-13 Axovant Sciences GmbH Dérivés d'arylhérétoaryl urée en tant que modulateurs du récepteur sérotoninergique 5-ht2a utiles pour la prophylaxie et le traitement d'hallucinations associées à une maladie neurodégénérative
WO2017202206A1 (fr) * 2016-05-27 2017-11-30 深圳市塔吉瑞生物医药有限公司 Composé quinoléine substitué et composition pharmaceutique correspondante

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
BRPI0308696B8 (pt) * 2002-03-27 2021-05-25 Axovant Sciences Gmbh composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos
GB0321473D0 (en) * 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
PT1667975E (pt) 2008-02-29
EP1667975B1 (fr) 2007-11-28
CO5680402A2 (es) 2006-09-29
AU2004283805A1 (en) 2005-05-06
BRPI0414678A (pt) 2006-11-28
DE602004010410T2 (de) 2008-10-16
IL174213A0 (en) 2006-08-01
RU2355681C2 (ru) 2009-05-20
PL1667975T3 (pl) 2008-04-30
GB0322629D0 (en) 2003-10-29
US20070032504A1 (en) 2007-02-08
MXPA06003375A (es) 2006-06-08
ZA200601453B (en) 2007-04-25
WO2005040124A1 (fr) 2005-05-06
NO20061791L (no) 2006-04-24
RU2006114024A (ru) 2007-11-10
CA2540022A1 (fr) 2005-05-06
IS8399A (is) 2006-04-05
DK1667975T3 (da) 2008-04-14
CN1856471A (zh) 2006-11-01
JP2007506702A (ja) 2007-03-22
DE602004010410D1 (en) 2008-01-10
ES2297465T3 (es) 2008-05-01
HK1094190A1 (en) 2007-03-23
EP1667975A1 (fr) 2006-06-14
HRP20080055T3 (en) 2008-02-29

Similar Documents

Publication Publication Date Title
TN2009000059A1 (fr) Formes de dosage pharmaceutiques orales anti-manipulation contenant un analgesique opioide
MA30999B1 (fr) Composés.
TNSN99006A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
TNSN00121A1 (fr) Composes nouveaux inhibiteurs de metalloproteases, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN01145A1 (fr) Derives d&#39;imidazole a noyau aryle ou heteroaryle condense, et compositions les contenant.
MA30232B1 (fr) Inhibiteurs de kinase bases sur l&#39;hydantoine
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
TNSN98084A1 (fr) Derives de macrolides substitues en position c-4
NO20050741L (no) Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
CA2407100A1 (fr) 1-aroyle-piperidinyle benzamidines
TNSN02009A1 (fr) Pyrimidinones bicycliques condensees nouvelles, inhibitrices de mmp, et compositions les contenant.
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
TN2009000138A1 (fr) Biaryl-ether-urees
TNSN99039A1 (fr) Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99106A1 (fr) Derives d&#39;isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA29692B1 (fr) Derives de la xanthine en tant qu&#39;agonistes selectifs du hm74a
TNSN98238A1 (fr) Macrolides nouveaux
TNSN99172A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN07275A1 (fr) Derives de triazole substitues, servant d&#39;antagonistes d&#39;ocytocine
TNSN99156A1 (fr) Derives d&#39;acide hydroxypipecolate-hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA30289B1 (fr) Dérivés d&#39;amines
TNSN97198A1 (fr) Derives de 6-phenylpyridyl-2- amine et compositions pharmaceutiques les contenant
TNSN99055A1 (fr) Derives bicycliques d&#39;acide hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant